Drug reference

pemigatinib

Mosby’s 2024 Nursing Drug Reference

Source: Mosby’s 2024 Nursing Drug Reference
PDF pages: 1036, 1037

Review source pages for extracted sections and age labels.

Overview

Names and pronunciation

(pem′i-ga′ti-nib) Penazyre Func. class: Antineoplastic, fibroblast growth factor receptor (FGFR) inhibitor

PDF page 1036

Uses

USES: Treatment of previously treated, unresectable, locally advanced/ metastatic cholangiocarcinoma with an FGFR 2 fusion or other rearrangement

PDF page 1036

Safety

Contraindications

CONTRAINDICATIONS: Hypersensitivity, pregnancy, breastfeeding

PDF page 1036

Dose and formulations

Dosage and routes

DOSAGE AND ROUTES Adult: PO: 13.5 mg daily on days 1-14 of a 21-day cycle; continue until disease progression or unacceptable toxicity See Appendix B PENICILLINS

PDF page 1037

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

pemigatinib

Mosby’s 2024 Nursing Drug Reference

Source: Mosby’s 2024 Nursing Drug Reference
PDF pages: 1036, 1037

Review source pages for extracted sections and age labels.

Overview

Names and pronunciation

(pem′i-ga′ti-nib) Penazyre Func. class: Antineoplastic, fibroblast growth factor receptor (FGFR) inhibitor

PDF page 1036

Uses

USES: Treatment of previously treated, unresectable, locally advanced/ metastatic cholangiocarcinoma with an FGFR 2 fusion or other rearrangement

PDF page 1036

Safety

Contraindications

CONTRAINDICATIONS: Hypersensitivity, pregnancy, breastfeeding

PDF page 1036

Dose and formulations

Dosage and routes

DOSAGE AND ROUTES Adult: PO: 13.5 mg daily on days 1-14 of a 21-day cycle; continue until disease progression or unacceptable toxicity See Appendix B PENICILLINS

PDF page 1037

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.